( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57



Dr. N. P. Rao*, Dr. Gita Nadimpalli and Dr. Shahu Ingole


Background: Hypertension (HTN) is ranked as third most important risk factor for attributable burden of cardiovascular disease. Azilsartan, because of highest responder rate, appears to be the most suited antihypertensive agent to achieve the target blood pressure (BP). As there is limited Indian clinical trial data and real-world studies on safety and effectiveness of azilsartan, this study was designed to investigate the ‘real-world’ effectiveness and safety of azilsartan in Indian hypertensive patients associated with various co-morbidities. Methods: This was a prospective, non-interventional, real-world study of Indian adult patients of diagnosed with essential HTN and prescribed with tablet azilsartan. Demographic data, details of treatment with azilsartan, changes in BP and occurrence of adverse events (AE) were noted during the follow-up visits (6 and 12 weeks). Results: Among 240 enrolled patients, mean reduction systolic BP from baseline with azilsartan was 16.2+11.1 mm Hg and 27.16+10.6 mm Hg (p<0.001) at Week 6 and Week 12 respectively. The proportion of patients achieving target systolic BP of ≤140 mm Hg was 56.70% at Week 12. The proportion of patients achieving aggressive target BP of <130/80 mm Hg was 40.42% at Week 12. In patients uncontrolled on telmisartan and shifted to azilsartan, the proportion of patients with target systolic BP of ≤140 mm Hg at Week 12 was 75%. Conclusion: The results of present real-world study suggest that azilsartan is effective and safe in the treatment of newly diagnosed treatment-naïve hypertensive patients as well as those uncontrolled on other antihypertensive agents including telmisartan with associated co-morbidities.

Keywords: Hypertension, azilsartan, blood pressure, telmisartan.

[Full Text Article]



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2021 Issue has been Published, Kindly check it on


    NOVEMBER Issue has been successfully launched on 1 November 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )